In fact, the persistently high 18F-FDG uptake after therapy is a reliable imaging biomarker of tumor resistance whereas the early reduction of tracer uptake during treatment does not univocally indicate tumor sensitivity to EGFR inhibitors since glucose metabolism and proliferation may be differently regulated depending on the cellular context. Here, EGFR is linked to neoplasm.